1. Efficacy and safety of remimazolam tosilate in anesthesia for short otolaryngology surgery
- Author
-
Wen Cheng, Yi Cheng, Hongying He, Dandan Zhou, Jing Wang, Yi Zhang, and Zhao Wang
- Subjects
Remimazolam tosilate ,General anesthesia ,Otolaryngology surgery ,Anesthesiology ,RD78.3-87.3 - Abstract
Abstract Background Remimazolam tosilate represents the novel ultrashort-acting benzodiazepine drug. This work focused on exploring whether remimazolam tosilate was effective and safe in anesthesia for short otolaryngology surgery in adults, and optimize its medication regimen, thus providing a theoretical basis for its widespread clinical application. Methods The present unicentric, double-blind, randomized controlled study enrolled altogether 85 otolaryngology surgery patients aged 18–60 years, and they were divided as remimazolam (RM, 42 cases) or midazolam (MD, 43 cases) group. Efficacy outcomes included successful sedation time, sedation effect (Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score), bispectral index values (BIS), and postoperative recovery. The safety outcomes were patient vital signs at each time point (before induction (T0), 2 min and 5 min after trial drug treatment (T1 and T2 separately), during successful intubation (T3), at the end of surgery (T4), during extubation (T5), and at the time of exiting the room (T6)), any adverse reactions (AEs) during perioperative period, and patient satisfaction with anesthesia experience. Results Demographics were not significantly different in both groups (P > 0.05). RM group had significantly decreased successful sedation time relative to MD group (P 0.05), but RM group exhibited decreased discharge time compared with MD group (P
- Published
- 2024
- Full Text
- View/download PDF